

NIFEREX- ferrous asparto glycinate, iron, ascorbic acid, folic acid, cyanocobalamin, zinc, and succinic acid tablet
Avion Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Iron Supplement

Niferex® Tablets

Rx Only Dietary Supplement

DESCRIPTION: Niferex® for oral administration is an iron supplement that is an oval, copper colored, coated tablet with "344" embossed on one side.

| Supplement Facts | | |
|--|--------------|----------------------|
| Serving Size: 1 tablet, Servings Per Container: 30 | | |
| Amount per Serving: | | % Daily Value |
| Vitamin C (as ascorbic acid) | 175 mg | 194% |
| Folate (as 1,4 mg Quatrefolic®(6S)-5, methyltetrahydrofolate glucosamine salt (equivalent to 750 mcg of folic acid) and folic acid, USP 250 mcg) | 1700 mcg DFE | 425% |
| Vitamin B12 (as cyanocobalamin) | 25 mcg | 1042% |
| Iron (as Sumalate® (ferrous asparto glycinate) | 75 mg | 417% |
| Zinc (as zinc-bisglycinate chelate) | 15 mg | 136% |
| Succinic Acid | 150 mg | † |

Percent Daily Values (DV) are based on a 2,000 calorie diet
† Daily Value not established

OTHER INGREDIENTS: Dicalcium phosphate dihydrate, microcrystalline cellulose, croscarmellose sodium, stearic acid, silicon dioxide, magnesium stearate. Coating contains: Candurin® Orange (FD&C Blue #1, FD&C Red #40, FD&C Yellow #6), HPMC, titanium dioxide and triacetin.

This product contains FD&C Yellow #6.

INDICATIONS: Niferex® is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.

CONTRAINDICATIONS: Niferex® is contraindicated in patients with a known hypersensitivity to any of the ingredients.

PRECAUTIONS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **KEEP THIS PRODUCT OUT OF REACH OF CHILDREN.** In case of accidental overdose, call a doctor or poison control center immediately.

ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSAGE AND ADMINISTRATION: One tablet daily, or as directed by a physician.

HOW SUPPLIED: Bottles of 30 tablets (75854-344-30). The listed product number is not a National Drug Code. Instead, Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and healthcare insurance computer systems.

STORAGE: Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature.]

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR INTENDED TO DIAGNOSE, PREVENT ANY DISEASE.

KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.

MANUFACTURED FOR:

Avion Pharmaceuticals, LLC

Alpharetta, GA 30005 1-888-61-AVION

L-0437 Rev. 0924-01

Quatrefolic® is a registered trademark of Gnosis, SpA. Covered by one or more claims of U.S. Patent #7,947,662 CAS #1181972-37-1

Sumalate® is a registered trademark of Albion Laboratories, Inc., covered by one or more claims of U.S. Patent Nos. 6,716,814, 8,007,846 and 8,425,956.

75854-344-30

Rx Only Dietary Supplement

30 Tablets

Sugar Free

Lactose Free

Niferex® Tablets (ferrous asparto glycinate)

www.niferex.com

| | | |
|---|------------------|--------|
| SUCCINIC ACID (UNII: AB6MNQ6J6L) (SUCCINIC ACID - UNII:AB6MNQ6J6L) | SUCCINIC ACID | 150 mg |
| INTRINSIC FACTOR (UNII: 70BT6OQT2Q) (INTRINSIC FACTOR - UNII:70BT6OQT2Q) | INTRINSIC FACTOR | 100 mg |

Inactive Ingredients

| Ingredient Name | Strength |
|---|----------|
| CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: O7TSZ97GEP) | |
| CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) | |
| CROSCARMELLOSE SODIUM (UNII: M28OL1HH48) | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | |
| STEARIC ACID (UNII: 4ELV7Z65AP) | |
| SILICON DIOXIDE (UNII: ETJ7Z6XBU4) | |
| FD&C BLUE NO. 1 (UNII: H3R47K3TBD) | |
| FD&C RED NO. 40 (UNII: WZB9127XOA) | |
| FD&C YELLOW NO. 6 (UNII: H77VEI93A8) | |
| HYDROXYPROPYL METHYLCELLULOSE (UNII: 3NXW29V3WO) | |
| TITANIUM DIOXIDE (UNII: 15FIX9V2JP) | |
| TRIACETIN (UNII: XHX3C3X673) | |

Product Characteristics

| | | | |
|-----------------|------------------------|---------------------|----------|
| Color | brown (copper colored) | Score | no score |
| Shape | OVAL | Size | 19mm |
| Flavor | | Imprint Code | 344 |
| Contains | | | |

Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---|----------------------|--------------------|
| 1 | NDC:75854-344-30 | 30 in 1 BOTTLE; Type 0: Not a Combination Product | 12/16/2024 | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------------|--|----------------------|--------------------|
| unapproved drug other | | 12/16/2024 | |

Labeler - Avion Pharmaceuticals, LLC (040348516)

Registrant - Avion Pharmaceuticals, LLC (965450542)

Establishment

| Name | Address | ID/FEI | Business Operations |
|----------------------------|---------|-----------|------------------------|
| Avion Pharmaceuticals, LLC | | 040348516 | manufacture(75854-344) |

